Education
About Us
Working with TipRanks
Follow Us
Instil Bio, Inc. (TIL)
:TIL
TIL Stock Chart & Stats
$19.08
-$1.87(-8.00%)
At close: 4:00 PM EST
$19.08
-$1.87(-8.00%)
Day’s Range― - ―
52-Week Range$10.69 - $42.79
Previous CloseN/A
Volume80.17K
Average Volume (3M)65.94K
Market Cap
$74.67M
Enterprise Value$125.66M
Total Cash (Recent Filing)$79.67M
Total Debt (Recent Filing)$84.92M
Price to Earnings (P/E)―
Beta5.29
Next Earnings
Mar 10, 2026EPS Estimate
-2.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding6,781,976
10 Day Avg. Volume54,676
30 Day Avg. Volume65,937
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-2.23
Enterprise Value/Market Cap1.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-166.88
Enterprise Value/Ebitda-1.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-11.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data ValidationMonotherapy data exceed expectations, validating PD-L1 × VEGF potential and leaving valuation upside.
Market PotentialValuation gap highlights upside potential for TIL.
Safety And DurabilityWith a clean safety profile, early durability, and a stark valuation gap, this dataset represents a compelling proof-of-concept.
Bears Say
Instil Bio News
TIL FAQ
What was Instil Bio, Inc.’s price range in the past 12 months?
Instil Bio, Inc. lowest stock price was $10.69 and its highest was $42.79 in the past 12 months.
What is Instil Bio, Inc.’s market cap?
Instil Bio, Inc.’s market cap is $74.67M.
When is Instil Bio, Inc.’s upcoming earnings report date?
Instil Bio, Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 81 days.
How were Instil Bio, Inc.’s earnings last quarter?
Instil Bio, Inc. released its earnings results on Nov 13, 2025. The company reported -$2.01 earnings per share for the quarter, beating the consensus estimate of -$2.355 by $0.345.
Is Instil Bio, Inc. overvalued?
According to Wall Street analysts Instil Bio, Inc.’s price is currently Overvalued.
Does Instil Bio, Inc. pay dividends?
Instil Bio, Inc. does not currently pay dividends.
What is Instil Bio, Inc.’s EPS estimate?
Instil Bio, Inc.’s EPS estimate is -2.42.
How many shares outstanding does Instil Bio, Inc. have?
Instil Bio, Inc. has 6,781,976 shares outstanding.
What happened to Instil Bio, Inc.’s price movement after its last earnings report?
Instil Bio, Inc. reported an EPS of -$2.01 in its last earnings report, beating expectations of -$2.355. Following the earnings report the stock price went down -7.205%.
Which hedge fund is a major shareholder of Instil Bio, Inc.?
Currently, no hedge funds are holding shares in TIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Instil Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
TIL Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $701.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.23%
12-Months-Change
Fundamentals
Return on Equity
-50.60%
Trailing 12-Months
Asset Growth
-22.30%
Trailing 12-Months
Company Description
Instil Bio, Inc.
Instil Bio is a biotechnology company focused on developing innovative cancer therapies. Specializing in tumor-infiltrating lymphocyte (TIL) technology, Instil Bio is dedicated to advancing cell therapy treatments that harness the power of the immune system to combat solid tumors. The company operates in the biopharmaceutical sector, aiming to provide novel therapeutic options for patients with unmet medical needs in oncology.
Technical Analysis
Zentalis Pharmaceuticals
―
Nkarta
―
ALX Oncology Holdings
―
Surrozen
―
TScan Therapeutics
―